Understanding inflammation in a genetic blood disorder linked to cancer risk
Official title: Determining how inflammation is regulated in RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancies
Funded at University of Pennsylvania · NIH-11069736 · Data updated 2026-11-12
This study is looking at how changes in a specific gene can cause ongoing inflammation in people with RUNX1 Familial Platelet Disorder, which may raise their chances of getting blood cancers, and the researchers hope to find new ways to help manage this inflammation and lower cancer risk for these patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $53,974 |
| NIH project number | 1F30HL178182-01 |
| Project ID | NIH-11069736 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with RUNX1 Familial Platelet Disorder who are at risk for hematologic malignancies.
✕Less likely to help
Patients without RUNX1 Familial Platelet Disorder or those not at risk for hematologic malignancies may not benefit from this research.
What this research studies
This research investigates how inherited mutations in the RUNX1 gene lead to chronic inflammation in patients with RUNX1 Familial Platelet Disorder (RUNX1-FPD), which increases their risk of developing blood cancers. By studying the genetic and epigenetic changes in blood cells, the researchers aim to uncover the mechanisms that drive this inflammatory response. The goal is to identify potential therapeutic strategies that could help control inflammation and reduce cancer risk in these patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent cancer in patients with RUNX1-FPD by targeting inflammation.
How similar studies have gone: Previous research has shown that targeting inflammation can be effective in other hematologic conditions, suggesting potential for success in this area as well.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Yen, Daniel — University of Pennsylvania
- Study coordinator: Yen, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.